DelveInsight’s, “Interleukin 6 Inhibitors - Pipeline Insight, 2022,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Interleukin 6 Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Interleukin 6 Inhibitors: Overview
Interleukin-6 (IL-6) is a protein produced by various cells. It helps regulate immune responses, which makes the IL-6 test potentially useful as a marker of immune system activation. IL-6 can be elevated with inflammation, infection, autoimmune disorders, cardiovascular diseases, and some cancers. The test measures the amount of IL-6 in the blood. Interleukin-6 is one of a large group of molecules called cytokines. Cytokines have multiple roles to play within the body and act especially within the immune system to help direct the body’s immune response. They are a part of the “inflammatory cascade” that involves the coordinated, sequential activation of immune response pathways. Anti-interleukin-6 agents are a class of therapeutics. Interleukin 6 is a cytokine relevant to many inflammatory diseases and many cancers. Hence, anti-IL6 agents have been sought. In rheumatoid arthritis they can help patients unresponsive to TNF inhibitors.
The companies and academics are working to assess challenges and seek opportunities that could influence Interleukin 6 Inhibitors R&D. The therapies under development are focused on novel approaches for Interleukin 6 Inhibitors.
This segment of the Interleukin 6 Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Interleukin 6 Inhibitors Emerging Drugs
Ziltivekimab: Novo Nordisk
Ziltivekimab is a fully human monoclonal antibody designed to lower systemic inflammation through inhibition of IL-6 (a pro-inflammatory cytokine with a causal role in atherosclerosis). With its extended half-life technology, ziltivekimab has been designed to enable once-monthly administration by subcutaneous (SC) injection. Ziltivekimab is being developed by Novo Nordisk following the acquisition of Corvidia Therapeutics, announced in June 2020.
Siltuximab: EUSA Pharma
Siltuximab is a monoclonal antibody that directly neutralizes interleukin (IL)-6, an inflammatory cytokine detected at elevated levels in multiple inflammatory conditions, of which potentially there may be a role in patients with COVID-19. It is currently approved by the FDA and the European Medicines Agency (EMA) as well as regulatory bodies in a number of other jurisdictions worldwide, for the treatment of patients with multicentric Castleman disease (MCD). Currently, it is in phase 3 stage of clinical trial evaluation to treat SARS-CoV-2 acute respiratory disease.
Further product details are provided in the report……..
This segment of the report provides insights about the different Interleukin 6 Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 15+ key companies which are developing the Interleukin 6 Inhibitors. The companies which have their Interleukin 6 Inhibitors drug candidates in the most advanced stage, i.e. Phase III include, Novo Nordisk.
DelveInsight’s report covers around 15+ products under different phases of clinical development like
Interleukin 6 Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Interleukin 6 Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Interleukin 6 Inhibitors drugs.
Current Scenario and Emerging Therapies:
Introduction
Executive Summary
Interleukin 6 Inhibitors: Overview
Pipeline Therapeutics
Therapeutic Assessment
Interleukin 6 Inhibitors – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Ziltivekimab: Novo Nordisk
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
FB 704A: Fountain BioPharma
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
PPV 06: Peptinov
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
KSI 501: Kodiak Sciences
Drug profiles in the detailed report…..
Inactive Products
Interleukin 6 Inhibitors Key Companies
Interleukin 6 Inhibitors Key Products
Interleukin 6 Inhibitors- Unmet Needs
Interleukin 6 Inhibitors- Market Drivers and Barriers
Interleukin 6 Inhibitors- Future Perspectives and Conclusion
Interleukin 6 Inhibitors Analyst Views
Interleukin 6 Inhibitors Key Companies
Appendix
List of Table
Table 1: Total Products for Interleukin 6 Inhibitors
Table 2: Late Stage Products
Table 3: Mid Stage Products
Table 4: Early Stage Products
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Product Type
Table 7: Assessment by Stage and Product Type
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: Inactive Products
List of Figures
Figure 1: Total Products for Interleukin 6 Inhibitors
Figure 2: Late Stage Products
Figure 3: Mid Stage Products
Figure 4: Early Stage Products
Figure 5: Preclinical and Discovery Stage Products
Figure 6: Assessment by Product Type
Figure 7: Assessment by Stage and Product Type
Figure 8: Assessment by Route of Administration
Figure 9: Assessment by Stage and Route of Administration
Figure 10: Assessment by Molecule Type
Figure 11: Assessment by Stage and Molecule Type
Figure 12: Inactive Products
• Novo Nordisk
• EUSA Pharma
• Celgene Corporation
• R-Pharm
• Emphycorp
• Fountain BioPharma
• Hutchison MediPharma
• Kodiak Sciences
• NeurMedix
• Kodiak Sciences
• Starton Therapeutics
• Peptinov
• Biocad
• Qyuns Therapeutics
• Bio-Thera Solutions
• Janssen Biotech
• Signpath Pharma
• CSL Behring
